11:12 AM EST - Aurinia Pharmaceuticals Inc. : Announced that new subgroup analyses from the completed AURORA pivotal trial of voclosporin were presented. The data were shared today at the European League Against Rheumatism (EULAR) 2020 E-Congress in an oral presentation given by Cristina Arriens, M.D., M.S.C.S., Clinical Assistant Member of the Arthritis and Clinical Immunology Research Program at the Oklahoma Medical Research Foundation. Aurinia Pharmaceuticals Inc.
shares T.AUP are trading down $0.27 at $20.26.
